Chan-Tack Kirk M, Truffa Melissa M, Struble Kimberly A, Birnkrant Debra B
Division of Antiviral Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
AIDS. 2007 May 31;21(9):1215-8. doi: 10.1097/QAD.0b013e32813aee35.
The risk of nephrolithiasis associated with atazanavir is not well characterized. The US Food and Drug Administration's Adverse Event Reporting System was searched for reports of nephrolithiasis in HIV-infected patients taking an atazanavir-based regimen. Thirty cases were identified. Many patients required hospitalization for management, including lithotripsy, ureteral stent insertion, or endoscopic stone removal. Some cases of nephrolithiasis resulted in atazanavir discontinuation. Healthcare professionals and patients should be informed that nephrolithiasis is a possible adverse event with atazanavir.
与阿扎那韦相关的肾结石风险尚未得到充分描述。检索了美国食品药品监督管理局的不良事件报告系统，以查找服用基于阿扎那韦方案的HIV感染患者中肾结石的报告。共识别出30例病例。许多患者需要住院治疗，包括体外冲击波碎石术、输尿管支架置入术或内镜下取石术。一些肾结石病例导致停用阿扎那韦。应告知医疗保健专业人员和患者，肾结石是阿扎那韦可能出现的不良事件。
